The U.S. Justice Department said settlements in which makers of brand-name drugs pay to delay the introduction of generic competitors should be considered illegal in many cases. The department, in a filing Monday with the 2nd U.S. Circuit Court of ...
Tagged with: Bayer AG brand-name drugs generic U.S. Department of Justice U.S. Federal Trade Commission U.S. Justice Department
Read More »